CFTR modulators and biologics have had a significant impact on the treatment of cystic fibrosis and severe asthma in recent years. Despite all the benefits that these active substances bring, some patients can also experience significant side effects. Some extrapulmonary consequences still receive too little attention in practice.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Pathophysiology, cardiovascular consequences and metabolic interventions
Obesity accelerates cardiovascular ageing
- CKD: counteracting kidney progression and reducing the risk of CVD
Targeted intervention through a multifactorial approach
- COPD therapy
Drug therapy – Update 2025
- Atrial fibrillation: interdisciplinary effort is crucial
Managing risk factors and comorbidities in addition to rhythm control
- Casuistry
Hernia turns out to be a 25 cm long Meckel’s diverticulum
- Side effects under opioid therapy
Is it possible to avoid the inevitable?
- Diagnostics of respiratory viral infections
What is tested when and on whom?
- From symptom to diagnosis